E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
A viral infection affecting the liver |
Infección viral que afecta al hígado |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. 2. To evaluate the safety and tolerability of MK-5172 in combination with MK-8742. |
1. Evaluar la eficacia de MK 5172 en combinación con MK 8742 mediante la proporción de sujetos que logren una RVS12 (respuesta virológica sostenida 12 semanas después del final de todo el tratamiento del estudio), que se define como una concentración de ARN del VHC < LIC (objetivo detectable no cuantificable [OD(nc)] u objetivo no detectable [OND]) 12 semanas después del final de todo el tratamiento del estudio. 2. Evaluar la seguridad y la tolerabilidad de MK 5172 en combinación con MK 8742. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 (+/-RBV) as assessed by the proportion of subjects achieving SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 24 weeks after the end of all study therapy. |
1. Evaluar la eficacia de MK 5172 en combinación con MK 8742 (+/ RBV) mediante la proporción de sujetos que logren una RVS24 (respuesta virológica sostenida 24 semanas después del final de todo el tratamiento del estudio), que se define como una concentración de ARN del VHC < LIC (OD(nc) u OND) 24 semanas después del final de todo el tratamiento del estudio. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The Sponsor will conduct Future Biomedical Research on specimens routinely and specifically collected during this clinical trial. This research may include genetic analyses (DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or the measurement of other analytes. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. |
El promotor llevará a cabo futuras investigaciones biomédicas con las muestras obtenidas de forma sistemática y específica durante este estudio clínico. Dichas investigaciones podrán incluir análisis genéticos (ADN), determinaciones de perfiles de expresión génica (ARN), proteómica, metabolómica (suero, plasma) y mediciones de otros analitos. Estas investigaciones tendrán por objeto el análisis de biomarcadores para abordar aspectos nuevos que no se describen en otras partes del protocolo (como parte del estudio principal) y solo se llevarán a cabo en muestras de los sujetos que hayan otorgado el consentimiento correspondiente. El objetivo de la obtención de muestras para futuras investigaciones biomédicas consiste en estudiar e identificar biomarcadores que proporcionen información a los científicos sobre las enfermedades y sus tratamientos |
|
E.3 | Principal inclusion criteria |
1. Be > or = to 18 years of age on day of signing informed consent. 2. HCV RNA (> or = to 10,000 IU/mL in peripheral blood) at the time of screening. 3. Have documented chronic HCV GT1, GT4, GT5 or GT6 4. Have had a liver biopsy, Fibroscan, or Fibrotest to check for cirrhosis 5. Have a previous HCV treatment status that is of non-response, partial response or treatment relapse 6. For HIV-1 co-infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit 7. For HIV-1 co-infection CD4+ T-cell count > 200 cells/mm3 at screening |
1.Tener mayor o igual a una edad mínima de 18 años el día de la firma del consentimiento informado. 2.Tener una concentración de ARN del VHC ( mayor o igual a10.000 UI/ml en sangre periférica) en el momento de selección 3.Tener una infección crónica documentada por el VHC GT1, GT4, GT5 o GT6 4.Disponer de una evaluación del estadio de la hepatopatía: Biopsia hepática, Fibroscan o Fibrotest para evaluar la presencia de cirrosis 5.Presentar un estado previo de tratamiento del VHC que se corresponda con una de las circunstancias siguientes: Respuesta nula, Respuesta parcial al tratamiento previo o Recidiva tras el tratamiento previo 6.En sujetos coinfectados por el VIH, presentar infección por el VIH 1, documentada con una prueba autorizada de detección rápida del VIH o un kit de inmunoanálisis de quimioluminiscencia (E/CIA). 7.En los sujetos coinfectados por el VIH, recuento de linfocitos T CD4+ > 200 células/mm3 en la selección |
|
E.4 | Principal exclusion criteria |
1. Has evidence of decompensated liver disease 2. Is coinfected with hepatitis B virus (e.g. HBsAg positive). 3. Has previous direct acting antiviral treatment. 4. Has signs of hepatocellular carcinoma or history of malignancy 5. Is taking or plans to take (a) any HIV therapy, or other medication not allowed for the study 6. Have an exclusionary laboratory value |
1.Presenten indicios de hepatopatía descompensada 2.Presenten una infección simultánea por el virus de la hepatitis B (por ejemplo, BsAg positivo). 3.Hayan recibido tratamiento antiviral previo de acción directa. 4.Tengan antecedentes de neoplasias malignas o signos de carcinoma hepatocelular 5.Estén tomando o tengan previsto tomar (a) cualquier tratamiento contra el VIH o (b) otros medicamentos prohibidos en el estudio. 6.Tengas valores de laboratorio que sean excluyentes |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects achieving SVR12 |
Proporción de sujetos con RVS12 (respuesta virológica sostenida 12 semanas) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
FU12 wk |
Seguimiento en la semana 12 |
|
E.5.2 | Secondary end point(s) |
The proportion of subjects achieving SVR24 |
Proporción de sujetos con RVS24 (respuesta virológica sostenida 24 semanas) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
FU24 wk |
Seguimiento en la semana 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Denmark |
France |
Netherlands |
New Zealand |
Australia |
Finland |
Korea, Republic of |
Malaysia |
Puerto Rico |
Spain |
Israel |
Poland |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |